Europe
The U.S. Food and Drug Administration (FDA) approved ViiV Healthcare’s Dovato, a once-a-day, single-tablet combination of dolutegravir (DTG) and lamivudine (3TC) for HIV-1 in adults who had not received treatment before.
Aresus takes over Veregen® business including API stock and intends to invest in expanding Veregen® into indications and markets
Positive HVAD LATERALTM Study Results Also Now Published in The Journal of Heart and Lung Transplantation
Panel composition is harmonized across species to allow translation of results from murine and human samples - from lab to clinic
Medigene AG announced its participation at the following upcoming networking and scientific conferences
In early March, Allergan reported that rapastinel, its experimental adjunctive treatment for major depressive disorder, failed to hit endpoints in a late-stage trial.
Company Has Initiated a Post-Approval Study of Heart Failure Management Best Practices to Further Demonstrate Improved Patient Outcomes
The highly successful thirteenth annual BIO-Europe Spring® international partnering conference wrapped up in Vienna, Austria, last week with a record 2,570 biotech, pharma and investment attendees who engaged in 15,428 one-to-one partnering meetings vying for over 3,600 licensing opportunities on offer.
In five years it is estimated that about 25,000 people in the United States will develop bronchiolitis obliterans syndrome (BOS), which results in respiratory failure and death. But a late-stage treatment under development by Breath Therapeutics could be a possible remedy for this rare and dread disease.
The FDA calendar has only one PDUFA data scheduled for the next couple weeks. On Thursday, April 11, the U.S. Food and Drug Administration (FDA) and Merck & Co. have a target action date for their supplemental Biologics License Application (sBLA) for Keytruda
PRESS RELEASES